What it sells
RBC-based liquid biopsy.
Business model breakdown
Workflow: what inputs become what output?
Draw a blood sample, analyse red-cell-bound DNA/RNA/protein biomarkers (cfDNA, tDNA), return same-day molecular result.
Economics: what it saves and how it charges
UnverifiedPre-commercial diagnostics developer; timeline shows FDA submissions 2024 to 2025; no revenue model stated.
Distribution: how it reaches customers
Early CLIA access, FDA submissions, partnership and licensing planned.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| 2026-09-01 | Seed | — | — | news.google.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.